Quantitative proteomic study of human prostate cancer cells with different metastatic potentials

QUN LI1*, YILEI LI2*, YANYING WANG3*, ZHENG CUI4, LULU GONG5, ZHIGANG QU6, YANPING ZHONG7, JUN ZHOU1, YING ZHOU1, YONG GAO1 and YULIN LI2

1Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120; 2The Key Laboratory of Pathobiology, Ministry of Education, Bethune Medical School, Jilin University, Changchun, Jilin 130021; Departments of 3Endoscopy in Special Clinic Room and 4Ultrasound, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120; 5The Hepatobiliary Pancreatic Surgery, Second Hospital of Jilin University, Changchun, Jilin 130041; 6The Spine Surgery, 7Department of Pathology, The First Hospital of Jilin University, Changchun, Jilin 130021, P.R. China

Received October 10, 2015; Accepted November 11, 2015

DOI: 10.3892/ijo.2016.3378

Correspondence to: Dr Yong Gao, Department of Oncology, Shanghai East Hospital, Tongji University School of Medicine, Shanghai 200120, P.R. China E-mail: gaoyon@hotmail.com

Dr Yulin Li, The Key Laboratory of Pathobiology, Ministry of Education, Bethune Medical School, Jilin University, Changchun 130021, Jilin 130021, P.R. China E-mail: ylli@jlu.edu.cn

*Contributed equally

Abstract. Metastatic dissemination is a feature of most cancers including prostate cancer (PCa), and is the main cause of treatment failure and mortality. The aim of the study is to explore the mechanisms of PCa metastasis and to search for potential prognostic markers using proteomics. Two-dimensional fluorescent differential gel electrophoresis (2D-DIGE) was used to quantify proteins in normal prostate epithelial cells, bone metastasis-derived PC-3 cells, and visceral metastasis-derived PC-3M cells. Metastatic potential was confirmed by flow cytometry, electron microscopy, proliferating cell nuclear antigen assay, and wound healing assay. Differential protein expression was compared between PCa cells with different metastatic potentials (LNcap, DU145, PC-3 and PC-3M) and normal prostate epithelial cells (RWPE-1). Selected candidate proteins in human prostate tissues were analyzed using GOA, UniProt and GeneCards analyses. Eighty-six proteins were differentially expressed between cell lines (>1.5-fold, P<0.05). Among them, twelve proteins were identified by MALDI-TOF-MS. One protein was upregulated in normal prostate epithelial cells, nine proteins were upregulated in PC-3, and two proteins were upregulated in PC-3M. Proteins were divided into five groups according to their functions. The SETDB1 protein was closely associated with the prognosis of PCa. Bioinformatics suggested that SETDB1 might promote PCa bone metastasis through the WNT pathway. In conclusion, SETDB1 might be associated with the development of bone metastases from PCa. Further study is necessary to assess its exact role in PCa.

Introduction

Prostate cancer (PCa) is the most common malignancy in males and the second cause of cancer-related death in the USA and Europe (1). The incidence and mortality of PCa are rapidly increasing in China because of changes in diet and aging of the population (2). The proportion of PCa diagnosed at its early stage has increased because of the widespread screening of serum prostate-specific antigen (PSA) in the last two decades (3). However, many patients still present metastases at diagnosis, and metastases are the first factor leading to death from PCa (4). Patients with metastases do not benefit from radical prostatectomy or radiotherapy (5,6). Therefore, novel treatment approaches are needed.

Proteomics is a powerful and effective tool to evaluate protein profiles (7). Two-dimensional fluorescent differential
enzymes in 0.02% EDTA. Cell number was adjusted to 1x10⁶ digested using trypsin and collected using 0.25% pancreatic enzymes involved in PCa metastatic spread might reveal new targets for the prevention and treatment of PCa metastases.

Materials and methods

Materials and chemical reagents. The human normal prostate tissue samples were obtained from autopsies. The human normal prostate cell line RWPE-1 and the human PCa cell lines PC-3, PC-3M, LNCap clone FGC, and DU145 were obtained from the American Type Culture Collection (ATCC) (Rockville, MD, USA). F12 and IMDM culture media were from Invitrogen (Carlsbad, CA, USA). K-SFM, RPMI-1640, and MEM culture media were from Gibco (Big Island, NY, USA). Acetonitrile (ACN), hACTH (18-39), and Ang III were from Sigma (St. Louis, MO, USA). Urea, SDS, glycine, Tris, bromophenol blue, ammonium persulfate, trypsin (sequencing grade), α-cyano-4-hydroxycinnamic acid (α-HCCA), trifluoroacetic acid (TFA), dithiothreitol (DTT), acrylamide, methylenebisacrylamide, CHAPS, thiourea, iodo-acetamide, Clean-up kit, 2D Quant kit, nuclease mix, PhastGel Blue tablets, immobiline pH-gradient (IPG) strip (pH 3.0-10.0), Pharmalyte (pH 3.0-10.0), IPG buffer (pH 3.0-10.0), and fluorescent dyes Cy2, Cy3, and Cy5 were from Amersham Biosciences-GE Healthcare (Uppsala, Sweden).

Cells and culture. The PC-3 cell line was cultured in F12 medium containing 10% fetal calf serum. The PC-3M cells were cultured in IMDM medium containing 10% fetal calf serum. Both media contained 2 mM glutamine, 50 U of penicillin, and 50 µg/ml of streptomycin. Cells were maintained at 37°C in a humidified atmosphere of 95% air and 5% CO₂. Adherent cells were washed three times, 5 min each time. The DAB solution was added. Peroxidase activity was blocked using 3% H₂O₂ at room temperature for 15 min. Cells were washed in PBS (pH 7.4) three times, 5 min each time. Non-immunologic animal serum was added, and the cells were incubated for 30 min at room temperature. Serum was discarded, and anti-mouse proliferating cell nuclear antigen (PCNA) monoclonal antibody (1:500) was added and incubated overnight at 4°C. Cells were washed in PBS three times, 5 min each time. The secondary antibody was added and incubated for 20 min at room temperature. Cells were washed in PBS three times, 5 min each time. Horseradish peroxidase-conjugated antibodies were added and incubated for 20 min at room temperature. Cells were washed in PBS three times, 5 min each time. The DAB solution was added. Cells were observed after 3-10 min using a light microscope.

Migration assay. Cells (1x10⁴) were seeded onto a Matrigel precoated 24-well plate and cultured to 95% confluence. A wound was created on the cell monolayers using a 10-µl micropipette tip and photographed at a magnification of x100. Monolayer cells with wounds were cultured in serum-free medium for 12 h and then photographed at the same position. The width of each cell wound was calculated using the ImageJ software program (National Institutes of Health, Bethesda, MD, USA).

Migration distance was calculated using the following formula: relative migration distance (%)
Protein extraction and quantification. Cells were collected and washed twice with ice-cold PBS. Lysis buffer (7 M urea, 2 M thiourea, 4% CHAPS, 30 mM Tris, pH 8.8) containing 1% protease inhibitors and nuclease mix was added. After pelleting the insoluble material by centrifugation at 25,000 x g for 30 min, the supernatants were collected. According to the manufacturer’s instructions, the protein samples were cleaned and quantified using the Clean-up and 2D Quant kits. Extracted proteins were stored at -20°C.

2D-DIGE. According to the manufacturer’s protocols, 50 µg of protein from each sample was minimally labeled with fluorescent dyes. After incubation on ice for 30 min, the reaction was terminated by adding 1 µl of 10 mM lysis. Cys3-, Cys5-, and Cy2-labeled samples and internal standards were pooled and the rehydration buffer (8 M urea, 2% CHAPS, 0.4% IPG buffer and 0.28% DTT) was added to obtain equal volumes. The samples were loaded on an IPG strip (24 cm, pH 3.0-10.0, linear) for isoelectric focusing (IEF) on an IGPPhor (Amersham Biosciences-GE Healthcare) at 20°C and 30 V for 12 h (rehydration), 500 V for 3 h, grad 1,000 V for 1 h, grad 8,000 V for 1 h, and 8,000 V for 3 h. After IEF, the strips were first equilibrated in an equilibration solution containing 50 mM Tris-HCl (pH 8.8), 6 M urea, 30% (v/v) glycerol, 2% (w/v) SDS and 1% (w/v) DTT for 15 min, and later in the same solution except that DTT was replaced by 4% (w/v) iodoacetamide for another 15 min. Then the IPG strips were loaded on 12.5% polyacrylamide gels using the Ettan DALT Six system (Amersham Biosciences-GE Healthcare) for electrophoresis at 1.5 W/gel overnight until the bromophenol blue front reached the bottom of the gels. Comparisons of protein expression in 2D images were performed with DeCyder software (GE Healthcare, Waukesha, WI, USA). The pixel volume of each spot was calculated, normalized and compared between groups. Each gel was matched with the internal standard to achieve minimal gel-gel variance. A cut-off value of a 1.5-fold was used.

Image analysis. Fluorescent images were collected using a Typhoon 9400 scanner (Amersham Biosciences-GE Healthcare) at a resolution of 100 µm. Matching, quantification, and statistics were carried out using DeCyder Differential In Gel Analysis software (Amersham Biosciences-GE Healthcare). Images were checked manually to eliminate artifacts. Then, gels were fixed in 20% trichloroacetic acid (TCA) overnight in stained with PhastGel Blue. Another three preparative gels of normal, PC-3 and PC-3M cells were made with 450 µg of protein and the same conditions. Spots of interest were excised from the DIGE analytic gels and preparative gels with the help of an Ettan Picker (Amersham Biosciences-GE Healthcare) for further identification.

Protein identification by MS/MS. Gel pieces were digested with trypsin in an Ettan Digestor (Amersham Biosciences-GE Healthcare). First, they were destained with 50 mM NH4HCO3 in 50% methanol and then dehydrated with 50% ACN-0.1% TFA. After the gel pieces had dried completely, trypsin (20 ng/µl in 20 mM NH4HCO3) was added and the samples were digested at room temperature overnight. The extracted peptides were removed, dried and resuspended in 50% ACN-0.1% TFA. Equal volumes of sample and α-HCCA were spotted and mixed on the MALDI-TOF MS target slides using an Ettan Spotter (Amersham Biosciences-GE Healthcare). Peptide extracts were analyzed on a MALDI-TOF MS (Amersham Biosciences-GE Healthcare) using the positive ion reflectron mode. The accelerating potential was 20 kV with eight shots per second. Trypsin autodigestion peaks were used as internal calibration and hACTH (19-39) and Ang III as external standards. Peptide mass data were searched against the National Center for Biotechnology Information (NCBI) database using the ProFound search engine (13) with the rat as the searched species. The basic requirement for identification was that the expectation value (chance of misidentification) was <0.05 and the coverage (the ratio of the protein sequence covered by the matched peptides) was >20%. The results were further confirmed in the Swiss-Prot protein database (us.expasy.org/sprot).

Functional classification of the identified proteins. The functional classification of the proteins was performed using GOA (http://www.ebi.ac.uk/goa) based on the protein accession numbers in IPI.

Immunoblotting. Proteins (20 µg) from PC-3, PC-3M, brain metastasis-derived PCa DU-145, lymph node metastasis-derived PCa LnCap, and normal human prostate RWPE-1 cell lines were analyzed by western blotting. After SDS-PAGE, proteins were electrotransferred to polyvinylidene fluoride membranes (Immobilon-P; Millipore, Bedford, MA, USA). The membranes were blocked for 1 h at room temperature in 5% non-fat dry milk in Tris-buffed saline and Tween-20, pH 7.5 (100 mM NaCl, 50 mM Tris, 0.1% Tween-20), and washed in Tris-buffed saline and Tween-20. Membranes were immunoblotted with: goat polyclonal anti-GRP78 (Santa Cruz Biotechnology, Santa Cruz, CA, USA), rabbit polyclonal anti-HSPA8 (Abgent Biotechnology, San Diego, CA, USA), rabbit polyclonal anti-TUBA1C (Abgent), goat polyclonal anti-HSP60 (Santa Cruz), rabbit polyclonal anti-PDIA3 (Abgent), rabbit polyclonal anti-desmin (Santa Cruz), mouse monoclonal anti-cytokeratin 18 (Santa Cruz), goat polyclonal anti-GRP 75 (Santa Cruz), mouse monoclonal anti-SETDB1/SETDB1 (Abcam Plc., Cambridge, UK) and glyceraldehyde-3-phosphate dehydrogenase (Santa Cruz). Primary antibodies were incubated at 4°C overnight, and secondary antibodies conjugated to horseradish peroxidase were incubated for 1 h at room temperature. The proteins were detected using an enhanced chemiluminescence detection system (Pierce, Rockford, IL, USA).

Immunohistochemistry. The UltraSensitive™ S-P immunohistochemistry (IHC) method was used to detect the expression of SETDB1 in PCa, prostate tissues bordering PCa, and bone metastases. Tissue microarrays were purchased from Xi’an Ailina Biotechnology Co., Ltd. (China). Antibody (SETDB1) was purchased from Abcam Plc. The hypersensitive UltraSensitive™ SP kit (rat/rabbit) was purchased from Maixin Biotechnology Co., Ltd. Samples were heated at 60°C for 30 min, dewaxed and hydrated. Antigen retrieval was performed in a 0.01 M citrate buffer (pH 6.0) for 2 min, cooled to room temperature, and washed with phosphate-buffered saline (PBS) 5 min, three times. Endogenous peroxidase...
was blocked with 3% H₂O₂ at room temperature for 10 min. Sections were washed with PBS for 5 min, three times. Normal non-immune sera was added at room temperature for 10 min and then discarded. The anti-SETDB1 antibody (1:200) was added and incubated at 4˚C overnight. Sections were washed with 0.1% Tween-20 PBS for 5 min, three times. Sections were incubated for 10 min at room temperature in Streptomyces avidin-peroxidase. DAB was added for 5 min, and washed with distilled water. Samples were counterstained with hematoxylin. Samples were dehydrated and mounted in neutral resin. Sections were examined by light microscopy. No color was negative (-), light brown was weakly positive (+), brown was positive (++), and tan was strongly positive (+++). The number of positive cells were <25% (+), between 25 and 49% (++) and >50% (+++). Sections were examined in ≥5-10 random fields.

Bioinformatics and network analysis of the SETDB1 protein. The function, subcellular location, domain, biological process, and pathway of the SETDB1 protein were analyzed using the UniProt (http://www.uniprot.org) and the GeneCards (http://www.genecards.org) databases. Functional network analysis of SETDB1 was performed using STRING (14) (version 9.0; http://string.embl.de) with the following analysis parameters: species Homo sapiens, confidence level of 0.400, and active prediction methods.

Statistical analysis. Data are expressed as means ± standard deviation (SD). Comparison between groups was performed using univariate analysis of variance with the Tukey's post hoc test. Statistical analysis was performed using GraphPad 5.0 (GraphPad software Inc., San Diego, CA, USA). P-values <0.05 were considered statistically significant.

Results

PC-3M cells have higher metastatic potential compare with PC-3 cells. The number of PC-3M cells in S phase was significantly higher compared with PC-3 cells. The S-phase fraction and the proliferation index were also significantly higher than the control group.

PC-3 cells were observed using transmission electron microscopy. PC-3 cells had a rich rough endoplasmic reticulum, glycogen particles, and sparse microtubule microfilaments. The PC-3M cells had abundant microvilli, rich cytoplasmic mitochondria, and their microtubules microfilaments were reduced and deficient.

PCNA IHC revealed that the PCNA expression in PC-3M cells was significantly higher than in PC-3 cells (P<0.01, n=5). The wound healing assay showed that the relative migration distance of the PC-3M cells was 50±8 compared with 33±5% for PC-3 cells.

2-DE protein maps of PCa cells. Fig. 1A-C is representative of 2D fluorescent gel images of normal prostate epithelial cells, PC-3 cells, and PC-3M cells, respectively. Among the proteins detected, 86 were changed by >1.5-fold. Of these 86 proteins, 12 were identified successfully by MALDI-TOF-MS (Fig. 1D). Spot 1,457 was identified as protein disulfide-isomerase A3 precursor, and was upregulated.

Table I. MALDI-TOF results of twelve differentially expressed proteins in prostate cancer.

<table>
<thead>
<tr>
<th>Spot no.</th>
<th>Expectationa</th>
<th>Accession no.</th>
<th>Cover Percentb</th>
<th>MW</th>
<th>PI</th>
<th>Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>1,144</td>
<td>0.000</td>
<td>gi 1143492</td>
<td>26.2%</td>
<td>72.210</td>
<td>5.0</td>
<td>78 kDa glucose-regulated protein precursor</td>
</tr>
<tr>
<td>1,480</td>
<td>0.001</td>
<td>gi 4204880</td>
<td>23.9%</td>
<td>70.260</td>
<td>5.6</td>
<td>Heat shock cognate 71 kDa protein</td>
</tr>
<tr>
<td>1,397</td>
<td>0.000</td>
<td>gi 340021</td>
<td>29.3%</td>
<td>49.895</td>
<td>4.9</td>
<td>Tubulin α-1C chain</td>
</tr>
<tr>
<td>1,400</td>
<td>0.000</td>
<td>gi 7702086</td>
<td>20.3%</td>
<td>61.360</td>
<td>5.7</td>
<td>60 kDa heat shock protein</td>
</tr>
<tr>
<td>1,457</td>
<td>0.001</td>
<td>gi11024686</td>
<td>20.3%</td>
<td>56.782</td>
<td>6.4</td>
<td>Protein disulfide-isomerase A3 precursor</td>
</tr>
<tr>
<td>1,560</td>
<td>0.001</td>
<td>gi 860986</td>
<td>30.5%</td>
<td>57.160</td>
<td>5.9</td>
<td>Protein disulfide-isomerase A3 precursor</td>
</tr>
<tr>
<td>1,768</td>
<td>0.000</td>
<td>gi 179279</td>
<td>28.4%</td>
<td>56.880</td>
<td>5.4</td>
<td>ATP synthase subunit β</td>
</tr>
<tr>
<td>1,573</td>
<td>0.000</td>
<td>gi19698555</td>
<td>26%</td>
<td>53.56</td>
<td>5.2</td>
<td>Desmin</td>
</tr>
<tr>
<td>1,765</td>
<td>0.000</td>
<td>gi12653819</td>
<td>30.5%</td>
<td>48.010</td>
<td>5.4</td>
<td>Keratin, type I cytoskeletal 18</td>
</tr>
<tr>
<td>2,088</td>
<td>0.000</td>
<td>gi 34039</td>
<td>28.7%</td>
<td>44.090</td>
<td>5.0</td>
<td>Keratin, type I cytoskeletal 19</td>
</tr>
<tr>
<td>1,242</td>
<td>0.000</td>
<td>gi 292059</td>
<td>26.1%</td>
<td>74.050</td>
<td>6.0</td>
<td>Stress-70 protein</td>
</tr>
<tr>
<td>2,288</td>
<td>0.000</td>
<td>gi 1592734</td>
<td>29.3%</td>
<td>9.990</td>
<td>5.6</td>
<td>Histone-lysine N-methyltransferase SETDB1</td>
</tr>
</tbody>
</table>

*The chance of incorrect identification. **The ratio of the protein sequence covered by the matched peptides.
Figure 1. 2D-DIGE images of proteins from different cell lines. (A) 2D-DIGE images and fluorescence of human normal prostate cells. (B) 2D-DIGE images and fluorescence of PC-3 cells. (C) 2D-DIGE images and fluorescence of PC-3M cells. (D) Fluorescence-labeled proteins were separated on 24x20-cm gels. Protein expressions were compared using DeCyder-BVA software. Eighty-six proteins were differentially expressed, which are labeled in green on the image. Twelve of these proteins were identified by MS.

Figure 2. Typical MALDI-TOF MS PMF spectrum of trypsin-digested spot 1,457, and its Swiss-Prot database results. (A) The peptide mass fingerprinting of protein disulfide-isomerase A3 precursor. Coverage is 20.3%. Expectation is 0.001. The x-axis represents the mass-to-charge ratio (m/z), and the y-axis represents the relative abundance. The peptide masses are labeled and annotated with their corresponding m/z. After calibration, the mass fingerprint spectrum data matched to human protein disulfide-isomerase A3 precursor, whose theoretical pI is 6.4 and molecular weight is 56,782 with the expectation value 0.001 (0.0% chance of an incorrect identification) and the protein sequence coverage was 20.3%. (B) PMF data of protein spot 1,457 were entered in the Swiss-Prot database. Results showed that it is the protein disulfide-isomerase A3 precursor. These results were consistent with the NCBI database search result.
data. In the present study, scores >55 were considered credible (P<0.05). The score of the protein disulfide-isomerase A3 precursor was 76 (Fig. 2B).

The identified proteins were divided into the following five groups according to their functions. i) Binding proteins: histone-lysine N-methyltransferase SETDB1 (SETDB1), heat shock 71 kDa protein (HSPA8), and 60 kDa heat shock protein (HSP60). ii) Apoptosis-related proteins: 78 kDa glucose-regulated protein precursor (GRP78), tubulin α-1C chain (TUBA1C), stress-70 protein (GRP75), and mitochondrial precursor. iii) Cytoskeletal proteins: desmin, keratin type I cytoskeletal 19 (CK-19), and keratin type I cytoskeletal 18 (CK-18). iv) Proteins with phospholipase c activity: protein disulfide-isomerase A3 precursor (PDIA3) and protein disulfide isomerase A3 precursor. v) Protein with transporter activity: ATP synthase subunit β (ATPB).

Differential expression of proteins in normal prostate epithelial cells, PCa cells, and PCa tissues. GRP78, HSPA8, TUBA1C, HSP60, PDIA3, desmin, CK-18, GRP75, and SETDB1 were detected in human normal prostate epithelial cells and in PC-3, PC-3M, LNCap and DU-145 cells by western blotting (Fig. 3). PDIA3 expression was consistent with the proteomic results in PC-3 and PC-3M cells, but was also highly expressed in normal cells; therefore, it was not a candidate protein for metastatic spread. The proteomics and western blot expression of CK-18 were consistent, it was highly expressed in PC-3 cells compared with PC-3M cells and normal cells. Whereas, SETDB1 was highly expressed in PC-3 and DU-145 cells, but it was hardly expressed in normal, LNCap, and PC-3M cells. Therefore, SETDB1 was considered as an important candidate protein for metastasis.

Subsequently, human prostate tissue chips were used to test the expression of SETDB1. The expression of SETDB1 in the PCa and bone metastases combo chip (PR956b) suggested that SETDB1 protein was expressed in the cytoplasm and nucleus of PCa. Its expression was closely correlated with Gleason grade, and with TNM staging (Fig. 4A). Irrespective of the TNM stage, in Gleason grade I, SETDB1 protein in PCa was weakly positive (+); in Gleason grade II, SETDB1 was strongly positive (++/+++); and in Gleason grade III, SETDB1 was more strongly positive (++++).

At the same time, SETDB1 protein was negative (-) in fibers, blood vessels, fat, smooth muscles, and bones. SETDB1 protein was weakly positive (+) in normal prostate and abdominal metastatic prostate cancer. SETDB1 was positive (++) in PCa bone metastasis tissue (Fig. 4B).

SETDB1 analysis by bioinformatics. SETDB1 is a member of the histone-lysine methyltransferase family, Suvar 3-9 subfamily. The protein contains two Tudor domains, one MBD (methyl-CpG-binding) domain, one pre-SET domain, one SET domain, and one post-SET domain. The pre-SET, SET, and post-SET domains are all required for the methyltransferase activity. A 347-amino acid insertion in the SET domain has no effect on the catalytic activity. In the pre-SET domain, Cys residues bind three zinc ions that are arranged in a triangular cluster. Some of these Cys residues contribute to the binding of two zinc ions within the cluster.

The biological process of the SETDB1 protein includes the following (from the UniProt database): bone development (Fig. 5A), inner cell mass cell proliferation (Fig. 5B), transcription, DNA-template, histone H3-K9 trimethylation, and negative regulation of transcription from RNA polymerase II promoter. Data from the Gene Cards database (http://www.genecards.org) revealed that the SETDB1 protein participates in three classical pathways: chromatin regulation/acetylation, non-canonical Wnt signaling pathway, and lysine degradation.

Furthermore, single protein analysis using String 9.0 software indicated that SETDB1 interacts with MBD1, which
is abolished when MBD1 is sumoylated. SETDB1 interacts with ATF7IP and ATF7IP2; the interaction with ATF7IP is required to stimulate histone methyltransferase activity and facilitate the conversion of dimethylated to trimethylated H3 ‘Lys-9’. During DNA replication, it is recruited by SETDB1 to form an S phase-specific complex that facilitates methylation of H3 Lys-9 during replication-coupled chromatin assembly and is at least composed of the CAF-1 subunit CHAF1A, MBD1, and SETDB1. SETDB1 interacts with ERG, TRIM28/TIF1B, CBX1, CBX5, CHD7, DNMT3A, HDAC1, HDAC2, NLK, PPARG, SIN3A, SIN3B, DNMT3B, and SUMO2. SETDB1 interacts with MPHOSPH8, and form part of a complex containing at least CDYL, REST, WIZ, SETB1, EHMT1, and EHMT2 (Fig. 6).

Figure 4. Detection of SETDB1 protein expression by immunohistochemistry. (A) Irrespective of the TNM stage, the higher the Gleason grade, the stronger SETDB1 protein expression level in the cytoplasm or nucleus of PCa tissue (x200). (B) SETDB1 IHC was negative in fibers, blood vessels, fat, smooth muscle and bone tissue. SETDB1 protein was weakly positive (+) in normal prostate tissue and abdominal metastatic prostate cancer tissues. It was positive in prostate cancer bone metastasis tissue.
Proteomics is a powerful approach for the identification of novel cancer biomarkers or key proteins (15,16). However, little is known about how tumor cells acquire the ability to spread to initiate metastases because of the complexity of the process. The present study aimed to identify proteins differentially expressed between normal prostate cells and two PCa cell lines with different metastatic potential by coupling LCM with 2D-DIGE. LCM is one of the best technologies for obtaining specific tissues (17-19). Eighty-six proteins were significantly different between the cell lines. Among them, twelve proteins were identified successfully by MALDI-TOF-MS. One protein was upregulated in normal prostate epithelial cells, nine proteins were upregulated in PC-3, and two proteins were upregulated in PC-3M. The SETDB1 protein was closely associated with the prognosis of PCa. Bioinformatics suggested that SETDB1 likely promotes PCa bone metastases through the WNT pathway.

Previously, traditional 2-DE proteomic studies of PCa identified a large number of differentially expressed proteins and
some were reported as potential markers for diagnosis of localized PCa (20-23). Some studies of 2D-DIGE-based proteomics focused to identify novel clinically relevant proteins in PCa (24-26). In the present study, compared with normal prostate epithelial cells, eleven differentially expressed proteins were identified as potential candidates associated with prostate cancer metastases. Of them, some were demonstrated to be related to PCa and other cancers in previous studies including ATP synthase subunit β (27, 28), heat shock protein (HSP) (29), stress-70 protein (30), keratin type I cytoskeletal 19 (31-34), keratin type I cytoskeletal 18 (35, 36), and TUBA1C (37). These results indicated that our proteomic strategy was an effective approach to identify key proteins closely associated with prostate cancer.

In the present study, SETDB1 was significantly elevated in human PCa PC-3 cells. SETDB1 is a member of the histone-lysine methyltransferase family, Suvar 3-9 subfamily. The SETDB1 protein is 1291-amino acid long, and is located in the nucleus and chromosomes. Members of this subfamily trimethylate Lys-9 of histone H3. H3 Lys-9 trimethylation represents a specific tag for epigenetic transcriptional repression by recruiting HP1 (CBX1, CBX3 and/or CBX5) proteins to methylated histones (38). This enzyme mainly functions in euchromatin regions, playing a central role in the silencing of euchromatic genes. H3 Lys-9 trimethylation is coordinated with DNA methylation. It probably forms a complex with MBD1 and ATF7IP that represses transcription and couples DNA methylation and histone Lys-9 trimethylation (39). Its activity is dependent on MBD1 and is heritably maintained through DNA replication by being recruited by CAF-1 (40). SETDB1 is targeted to histone H3 by TRIM28/TIF1β, a factor recruited by KRAB zinc-finger proteins (41).

SETDB1 is highly upregulated in patients with Huntington’s disease, suggesting that it participates in the altered chromatin modulation and transcription dysfunction observed in Huntington’s disease (42). SETDB1 has been established as an oncogene in a number of human carcinomas. A study has demonstrated the role of histone lysine methyltransferases SUV39H1 and SETDB1 in gliomagenesis and its association with cell proliferation, migration, and colony formation (43). Another study found that SETDB1 positively stimulated the WNT/β-catenin pathway and decreased P53 expression, resulting in enhanced non-small cell lung cancer growth in vitro and in vivo (44). Some authors have shown that miR-7, which is downregulated in the breast cancer MCF-7 and MDA-MB-231 cell lines, inhibited cell invasion and metastasis, decreased the breast cancer stem cell population, and partially reversed the epithelial-mesenchymal transition in MDA-MB-231 cells by directly targeting SETDB1 (45). In addition, SETDB1 is a candidate gene for melanoma susceptibility (46).

Recently, a study examined the function of SETDB1 in PCa (47), and has shown that silencing SETDB1 in 22RV-1 PCa cells inhibited PCa cell proliferation, migration, and invasion. However, the SETDB1 pathway is not clear, and its involvement in PCa metastases is even less clear. Using bioinformatics, it is known that SETDB1 participates in the process of bone development and inner cell mass proliferation. The data from the GeneCards database show that the SETDB1 protein is involved in three classical pathways: chromatin regulation/acetylation, non-canonical Wnt signaling, and lysine degradation. A number of studies suggest that SETDB1 promotes tumorigenesis and metastasis through the WNT/β-catenin pathway (44, 47). However, further studies are required to assess this point.

The present study is not without its limitations. Results were obtained by bioinformatics and need to be confirmed in cell and animal models. The results of the present study were mostly obtained from cell lines, and should be confirmed in a complete set of actual PCa obtained from patients.

In conclusion, SETDB1 might be associated with the development of bone metastases from PCa. Further study is necessary to assess its exact role in PCa and its involvement in the WNT pathway.

Acknowledgements

This study was supported by the Science and Technology Development Foundation from Pudong New District, Shanghai, China (PKJ2012-Y11), the Natural Science Foundation of Shanghai (14ZR1433900), the Outstanding Young Foundation from Pudong New District, Shanghai, China (PWQg2011-16), the Shanghai medical key specialty (ZK2012A26), Key Disciplines Group Construction Project of Pudong Health Bureau of Shanghai (PWZxq2014-04) and National Natural Science Foundation of China (81502288).

References


1446


